From: PARP inhibitors in the management of breast cancer: current data and future prospects
Compound | Adverse event (range of occurrence across studies) | |
---|---|---|
Grade 1–2 | Grade 3–4 | |
Nausea (32–58 %) |  | |
Fatigue (30–50 %) |  | |
Vomiting (11–34 %) | Nausea (4–15 %) | |
Anorexia (12–27 %) | Fatigue (5–15 %) | |
Anemia (5–25 %) | Anemia (11–15 %) | |
Headache (22 %) | Vomiting (4–11 %) | |
Diarrhea (11–18 %) | Thrombocytopenia (3 %) | |
Taste alteration (13 %) | Â | |
Veliparib [135] | Dizziness (7 %) | – |
Nausea (7 %) | ||
Dysgeusia (7 %) | ||
Talazoparib [32] | Fatigue (26 %) | Â |
Nausea (26 %) | Â | |
Alopecia (grade 1 only, 26 %) | Neutropenia (8 %) | |
Anemia (13 %) | Thrombocytopenia (8 %) | |
Neutropenia (10 %) | Anemia (5 %) | |
Flatulence (10 %) | Â | |
Thrombocytopenia (3 %) | ||
Niraparib [31] | Anemia (48 %) | Â |
Nausea (42 %) | Â | |
Thrombocytopenia (35 %) | Thrombocytopenia (15 %) | |
Fatigue (34 %) | Anemia (10 %) | |
Anorexia (25 %) | Fatigue (8 %) | |
Neutropenia (24 %) | Neutropenia (4 %) | |
Constipation (23 %) | Â | |
Vomiting (19 %) | Â | |
Insomnia (10 %) | Â | |
Rucaparib [33]a | Fatigue (30–39 %) | |
Nausea (27–30 %) | ||
Diarrhea (13–20 %) | ||
Vomiting (23 %) | ||
Dizziness (17 %) | ||
Anorexia (11 %) |